Daniel R. Scoles, PhD

Research Interests

  • Spinocerebellar Ataxias
  • Amyotrophic Lateral Sclerosis
  • Parkinson's Disease


  • English

Academic Information

  • Departments: Neurology - Associate Professor

Academic Office Information

  • 801-585-0694
  • Clinical Neurosciences Center
    175 North Medical Drive East
    Salt Lake City, UT 84132

Academic Bio

Daniel R. Scoles, PhD is Associate Professor of Neurology. His scientific training includes biochemistry, genetics of natural populations, and neurology with emphasis on brain tumor research. Dr. Scoles’s research objectives are centered on the identification of drugs for the treatment of spinocerebellar ataxia type 2 (SCA2) and Parkinson’s disease. Drug discovery methodologies used by Dr. Scoles include quantitative high throughput screening (qHTS) and antisense oligonucleotide screening. His research is promoted by collaborative partnerships with industry and the National Institutes of Health (NCATS). Dr. Scoles also investigates molecular mechanisms of disease gene expression control aimed at identifying new therapeutic targets and understanding drug action. Dr. Scoles is currently supported by grants from the NINDS.SPECIALTIES: Drug Discovery, Molecular Cellular and Organismal Biology.

Education History

Type School Degree
Postdoctoral Fellowship Cedars- Sinai Medical Center
Rose Moss Neuroscience Fellowship
Postdoctoral Fellow
Postdoctoral Fellowship Cedars-Sinai Medical Center
UCLA-CSMC Intercampus Medical Genetics Training Program
Postdoctoral Fellow
Doctoral Training The College of William and Mary
Population Genetics
Graduate Training The College of William and Mary
Marine Sciences
Undergraduate University of California Riverside

Selected Publications

Journal Article

  1. Scoles DR, Meera P, Schneider M, Paul S, Dansithong W, Figueroa KP, Hung G, Rigo F, Bennett CF, Otis TS, Pulst SM (2017). Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature, 544, 362-366.
  2. Pflieger LT, Dansithong W, Paul S, Scoles DR, Figueroa K, Meera P, Otis TS, Facelli JC, Pulst SM (2017). Gene co-expression network analysis for identifying modules and functionally enriched pathways in SCA2. [Epub ahead of print]. Hum Mol Genet.
  3. Wen J, Scoles DR, Facelli JC (2017). Molecular dynamics analysis of aggregation propensity of polyglutamine segments. PLoS ONE, 12(5), e0178333.
  4. Wen J, Scoles DR, Facelli J (2016). Effects of the enlargement of poly-glutamine segments on the structure and folding of ataxin-2 and ataxin-3 proteins. J Biomol Struct Dyn, May 20, 1-16.
  5. Figueroa KP, Paul S, Cal T, Lopreiato R, Karan S, Frizzarin M, Ames D, Zanni G, Brini M, Dansithong W, Milash B, Scoles DR, Carafoli E, Pulst SM (2016). Spontaneous Shaker rat mutant – A new model for X-linked tremor ataxia. Dis. Models Mech, 9(5), 553-562.
  6. Dansithong W, Paul S, Ho MHT, Scoles DR, Pulst SM, Huynh DP (2015). Generation of SCNA cell models using zinc finger nuclease (ZFN) technology for efficient high-throughput drug screening. PLoS ONE, 10(8), e0136930.
  7. Dansithong W, Paul S, Figueroa KP, Rinehart MD, Wiest S, Pfleiger LT, Scoles DR, Pulst SM (2015). Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. PLoS Genet, 11(4), e1005182.
  8. Scoles DR, Ho MHT, Dansithong W, Pflieger LT, Petersen LW, Thai KK, Pulst SM (2015). Repeat associated non-AUG translation (RAN translation) in ATXN2 is dependent on sequence downstream of the ATXN2 CAG repeat. PLoS ONE, 10(6), e0128769.
  9. Matilla-Dueas A, Ashizawa T, Brice A, Magri S, McFarland KN, Pandolfo M, Pulst SM, Riess O, Rubinsztein DC, Schmidt J, Schmidt T, Scoles DR, Stevanin G, Taroni F, Underwood BR, Snchez I (2014). Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias. Cerebellum, 13(2), 269-302.
  10. Wen J, Scoles DR, Facelli JC (2014). Structure Prediction of Polyglutamine Disease Proteins: Comparison of Methods. BMC Bioinformatics, 15 Suppl 7.
  11. Scoles DR, Pflieger LT, Thai KK, Hansen ST, Dansithong W, Pulst SM (2012). ETS1 regulates expression of ATXN2. Hum Mol Genet, 21(23), 5048-65.
  12. Scoles DR, Xu X, Wang H, Tran H, Taylor-Harding B, Li A, Karlan BY (2010). Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein. Gynecol Oncol, 116(1), 109-116.
  13. Elmore RG, Ioffe Y, Scoles DR, Karlan BY, Li AJ (2008). Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol, 111(1), 102-105.
  14. Walsh CS, Ogawa S, Scoles DR, Miller CW, Kawamata N, Narod SA, Koeffler HP, Karlan BY (2008). Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas. Clin Cancer Res, 14(23), 7645-51.
  15. Li AJ, Scoles DR, Armstrong KU, Karlan BY (2008). Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. Gynecol Oncol, 109(2), 220-5.
  16. Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, Sanada M, Nannya Y, Slamon DJ, Koeffler HP, Karlan BY (2008). ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol, 26(18), 2952-8.
  17. Scoles DR, Pavelka J, Cass I, Tran H, Baldwin RL, Armstrong K, Karlan BY (2007). Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. Gynecol Oncol, 104(1), 120-8.
  18. Scoles DR, Yong WH, Qin Y, Wawrowsky K, Pulst SM (2006). Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c). Hum Mol Genet, 15(7), 1059-70.
  19. Oh M-K, Scoles DR, Pulst SM (2005). DNA microarray analysis of immediate response to EGF treatment in rat schwannoma cells. Biotechnology and Bioprocess Engineering, 10(5), 444-450.
  20. Scoles DR, Qin Y, Nguyen V, Gutmann DH, Pulst SM (2005). HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line. Biochem Biophys Res Commun, 335(2), 385-92.
  21. Huynh DP, Scoles DR, Nguyen D, Pulst SM (2003). The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum Mol Genet, 12(20), 2587-97.
  22. Oh MK, Scoles DR, Haipek C, Strand AD, Gutmann DH, Olson JM, Pulst SM (2003). Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays. J Cell Biochem, 90(5), 1068-78.
  23. Scoles DR, Chen M, Pulst SM (2002). Effects of Nf2 missense mutations on schwannomin interactions. Biochem Biophys Res Commun, 290(1), 366-74.
  24. Sun CX, Haipek C, Scoles DR, Pulst SM, Giovannini M, Komada M, Gutmann DH (2002). Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet, 11(25), 3167-78.
  25. Scoles DR, Nguyen VD, Qin Y, Sun CX, Morrison H, Gutmann DH, Pulst SM (2002). Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet, 11(25), 3179-89.
  26. Gutmann DH, Haipek CA, Burke SP, Sun CX, Scoles DR, Pulst SM (2001). The NF2 interactor, hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), associates with merlin in the "open" conformation and suppresses cell growth and motility. Hum Mol Genet, 10(8), 825-34.
  27. Scoles DR, Huynh DP, Chen MS, Burke SP, Gutmann DH, Pulst SM (2000). The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet, 9(11), 1567-74.
  28. Huynh DP, Scoles DR, Ho TH, Del Bigio MR, Pulst SM (2000). Parkin is associated with actin filaments in neuronal and nonneural cells. Ann Neurol, 48(5), 737-44.
  29. Austin HM, Scoles D, Abell AJ (1999). Morphometric separation of annual cohorts within mid-Atlantic bluefish, Pomatomus saltatrix, using discriminant function analysis. Fishery Bulletin, 97, 411-420.
  30. Scoles DR, Graves JE, Collette BB (1998). Global phylogeography of mackerels of the genus Scomber. Fish. Bull. (Wash. D. C.), 96, 823-842.
  31. Scoles DR, Huynh DP, Morcos PA, Coulsell ER, Robinson NG, Tamanoi F, Pulst SM (1998). Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin. Nat Genet, 18(4), 354-9.
  32. Scoles DR, Baser ME, Pulst SM (1996). A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes. Neurology, 47(2), 544-6.
  33. Scoles DR, Graves JE (1993). Genetic analysis of the population structure of yellowfin tuna Thunnus albacares in the Pacific Ocean. Fishery Bulletin, 91, 690-698.
  34. Graves JE, McDowell JR, Beardsley AM, Scoles DR (1992). Stock structure of the bluefish, Pomatomus saltatrix, along the mid-Atlantic coast. Fishery Bulletin, 90, 703-710.


  1. Scoles DR (2008). The merlin interacting proteins reveal multiple targets for NF2 therapy. [Review]. Biochim Biophys Acta, 1785(1), 32-54.

Book Chapter

  1. Scoles DR, Das A, Pulst SM (2007). “Primary Tumors of the Nervous System”. In Rimoin DL, Connor JM, Pyeritz RE, Korf BR (Eds.), Emory and Rimoin's Principals and Practice of Medical Genetics (5th Edition, pp. 2879-2894). New York: Livingstone Churchill.
  2. Scoles DR, Pulst SM (2003). “Brain Tumors, Genetics”. In Aminoff M, Daroff R (Eds.), Encyclopedia of the Neurological Sciences (1, pp. 470-472). San Diego: Academic Press.
  3. Pulst SM, Scoles DR (2002). “Primary Tumors of the Nervous System”. In Rimoin DL, Connor JM, Pyeritz RE, Korf BR (Eds.), Emory and Rimoin's Principals and Practice of Medical Genetics (4th Edition, pp. 3231-3249). New York: Livingstone Churchill.